Measles Vaccine at 9 months of age

Medical Research Council Unit, The Gambia · Phase 1 active Biologic Quality 18/100

Measles Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia. It is currently in Phase 1 development. Also known as: MV.

The measles vaccine is a live, attenuated vaccine component used to prevent measles. It is administered to healthy individuals, including toddlers, as part of a booster injection, such as in the DTaP/IPV/Hib vaccine.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

• Baseline phase 1 → approval rate +9.6pp
  Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Measles Vaccine at 9 months of age
Also known as	MV
Sponsor	Medical Research Council Unit, The Gambia
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

• Upper respiratory tract infection
• Pyrexia
• Gastroenteritis
• Irritability
• Pain
• Redness
• Drowsiness
• Loss of appetite
• Malaria
• Rhinitis
• Respiratory tract infection
• Otitis media

Key clinical trials

• A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
• Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. (PHASE4)
• Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
• Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
• The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency (NA)
• A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
• Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines (PHASE1)
• Infant Malaria Vaccine Schedule Optimization (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Measles Vaccine at 9 months of age CI brief — competitive landscape report
• Measles Vaccine at 9 months of age updates RSS · CI watch RSS
• Medical Research Council Unit, The Gambia portfolio CI

Frequently asked questions about Measles Vaccine at 9 months of age

What is Measles Vaccine at 9 months of age?

Measles Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia.

Who makes Measles Vaccine at 9 months of age?

Measles Vaccine at 9 months of age is developed by Medical Research Council Unit, The Gambia (see full Medical Research Council Unit, The Gambia pipeline at /company/medical-research-council-unit-the-gambia).

Is Measles Vaccine at 9 months of age also known as anything else?

Measles Vaccine at 9 months of age is also known as MV.

What development phase is Measles Vaccine at 9 months of age in?

Measles Vaccine at 9 months of age is in Phase 1.

What are the side effects of Measles Vaccine at 9 months of age?

Common side effects of Measles Vaccine at 9 months of age include Upper respiratory tract infection, Pyrexia, Gastroenteritis, Irritability, Pain, Redness.

Related

• Manufacturer: Medical Research Council Unit, The Gambia — full pipeline
• Also known as: MV